Literature DB >> 23612856

Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients.

Yuki Ohishi1, Makoto Nakamuta, Naoko Ishikawa, Ohki Saitoh, Hitomi Nakamura, Yoshihiro Aiba, Atsumasa Komori, Kiyoshi Migita, Hiroshi Yatsuhashi, Nobuyoshi Fukushima, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuizumi, Makoto Ishibashi, Takashi Nishino, Ken Shirabe, Akinobu Taketomi, Yoshihiko Maehara, Hiromi Ishibashi, Minoru Nakamura.   

Abstract

BACKGROUND: To identify the genetic factors involved in the pathogenesis of primary biliary cirrhosis (PBC), we focused on the organic cation transporter 1 (OCT1/SLC22A1), which is closely associated with phosphatidylcholine synthesis in hepatocytes.
METHODS: We selected four (rs683369, rs2282143, rs622342 and rs1443844) OCT-1 single nucleotide polymorphisms (SNPs), and genotyped these SNPs using the TaqMan probe method in 275 Japanese PBC patients and 194 gender-matched, healthy volunteers as controls.
RESULTS: The Chi-square test revealed that the rs683369 variant allele (G) was associated with insusceptibility to PBC development [P = 0.009, odds ratio (OR) 0.60, 95 % confidence interval (CI) 0.40-0.88] in an allele model, and that the rs683369 variant allele (G) was associated with jaundice-type progression in a minor allele dominant genotype model (P = 0.032, OR 3.10, 95 % CI 1.05-9.14). The OCT-1 rs2282143 variant (T) and rs622342 variant (C) were also associated with jaundice-type progression in a minor allele recessive genotype model (P = 0.0002, OR 10.58, 95 % CI 2.36-47.54, and P = 0.006, OR 7.84, 95 % CI 1.39-44.36, respectively). Furthermore, the association of OCT-1 rs683369 and rs622342 with susceptibility to jaundice-type progression was confirmed by a replication study with a distinct set of PBC patients who underwent liver transplantation.
CONCLUSIONS: The present study is the first report on the association of OCT-1 genetic polymorphisms with the overall development and jaundice-type progression of PBC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23612856     DOI: 10.1007/s00535-013-0795-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  51 in total

Review 1.  Choline transport for phospholipid synthesis.

Authors:  Vera Michel; Zongfei Yuan; Shobha Ramsubir; Marica Bakovic
Journal:  Exp Biol Med (Maywood)       Date:  2006-05

2.  Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions.

Authors:  Takeshi Sakata; Naohiko Anzai; Ho Jung Shin; Rie Noshiro; Taku Hirata; Hirokazu Yokoyama; Yoshikatsu Kanai; Hitoshi Endou
Journal:  Biochem Biophys Res Commun       Date:  2004-01-16       Impact factor: 3.575

3.  The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood.

Authors:  E Jacquemin; J M De Vree; D Cresteil; E M Sokal; E Sturm; M Dumont; G L Scheffer; M Paul; M Burdelski; P J Bosma; O Bernard; M Hadchouel; R P Elferink
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

4.  MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine.

Authors:  A van Helvoort; A J Smith; H Sprong; I Fritzsche; A H Schinkel; P Borst; G van Meer
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis.

Authors:  A Tanaka; S Quaranta; A Mattalia; R Coppel; F Rosina; M Manns; M E Gershwin
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

6.  Single-nucleotide polymorphism analysis of the multidrug resistance protein 3 gene for the detection of clinical progression in Japanese patients with primary biliary cirrhosis.

Authors:  Yuki Ohishi; Minoru Nakamura; Naomi Iio; Shingo Higa; Mao Inayoshi; Yoshihiro Aiba; Atsumasa Komori; Katsuhisa Omagari; Hiromi Ishibashi; Kazuhiro Tsukamoto
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

7.  The effects of bilirubin on the thermal properties of phosphatidylcholine bilayers.

Authors:  S Ali; D Zakim
Journal:  Biophys J       Date:  1993-07       Impact factor: 4.033

8.  Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.

Authors:  Gideon M Hirschfield; Xiangdong Liu; Chun Xu; Yue Lu; Gang Xie; Yan Lu; Xiangjun Gu; Erin J Walker; Kaiyan Jing; Brian D Juran; Andrew L Mason; Robert P Myers; Kevork M Peltekian; Cameron N Ghent; Catalina Coltescu; Elizabeth J Atkinson; E Jenny Heathcote; Konstantinos N Lazaridis; Christopher I Amos; Katherine A Siminovitch
Journal:  N Engl J Med       Date:  2009-05-20       Impact factor: 91.245

9.  Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse.

Authors:  R P Oude Elferink; R Ottenhoff; M van Wijland; J J Smit; A H Schinkel; A K Groen
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  Primary biliary cirrhosis is associated with a genetic variant in the 3' flanking region of the CTLA4 gene.

Authors:  Brian D Juran; Elizabeth J Atkinson; Erik M Schlicht; Brooke L Fridley; Konstantinos N Lazaridis
Journal:  Gastroenterology       Date:  2008-07-01       Impact factor: 22.682

View more
  5 in total

1.  PharmGKB summary: very important pharmacogene information for SLC22A1.

Authors:  Srijib Goswami; Li Gong; Kathleen Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

Review 2.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

3.  STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis.

Authors:  Satoru Joshita; Takeji Umemura; Minoru Nakamura; Yoshihiko Katsuyama; Soichiro Shibata; Takefumi Kimura; Susumu Morita; Michiharu Komatsu; Akihiro Matsumoto; Kaname Yoshizawa; Hiromi Ishibashi; Eiji Tanaka; Masao Ota
Journal:  Dis Markers       Date:  2014-02-04       Impact factor: 3.434

4.  The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients.

Authors:  Di Xiao; Yu Guo; Xi Li; Ji-Ye Yin; Wei Zheng; Xin-Wen Qiu; Ling Xiao; Rang-Ru Liu; Sai-Ying Wang; Wei-Jing Gong; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Int J Endocrinol       Date:  2016-02-10       Impact factor: 3.257

5.  Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients.

Authors:  Wangqing Chen; Xu Zhang; Wei Zhang; Cong Peng; Wu Zhu; Xiang Chen
Journal:  Sci Rep       Date:  2018-09-04       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.